Rubraca (Rucaparib)

Save over 75% buying Rubraca generic from insulinhub today!

For more info on generic medicines made by Zydus Cadilla click here

For brand name Rubraca: Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

There are 2 approved Manufacturers in Europe: Almac Pharma Services Limited Seagoe Industrial Estate, Portadown, Craigavon, BT63 5UA United Kingdom Almac Pharma Services (Ireland) Ltd Finnabair Industrial Estate Dundalk County Louth A91 P9KD Ireland

Information about Rubraca (Rucaparib)

Rubraca (generic name: Rucaparib) is a medication used in the treatment of certain types of cancers, specifically ovarian cancer. It is a poly (ADP-ribose) polymerase (PARP) inhibitor that works by interfering with the ability of cancer cells to repair their DNA, leading to their death. Rubraca is particularly effective in patients with tumors that have BRCA gene mutations or other DNA repair deficiencies. It can be used as a monotherapy or in combination with other treatments for specific types of cancer.

Product Highlights

• Rubraca is primarily used for the treatment of recurrent ovarian cancer in patients with BRCA mutations who have been previously treated with chemotherapy.
• It can be used in patients with advanced ovarian cancer as maintenance therapy following chemotherapy.
• Rubraca is also approved for certain cases of metastatic castration-resistant prostate cancer (mCRPC) in patients with BRCA1/2 mutations.
• In some cases, Rubraca is used to treat breast cancer in patients with germline BRCA mutations.

Key Ingredient

• Rucaparib

Key Benefits

• Rubraca targets specific genetic mutations (e.g., BRCA1/2 mutations) that are common in certain cancers, offering a more personalized and effective treatment option.
• Rubraca has been shown to improve progression-free survival in patients with ovarian cancer, particularly in those with BRCA mutations.
• Unlike traditional chemotherapy, Rubraca offers a non-cytotoxic approach to cancer treatment, meaning it is less likely to harm healthy cells.
• Rubraca can be used in advanced cases of ovarian cancer or prostate cancer, particularly in patients with DNA repair deficiencies.

Direction of Use

• Rubraca is taken orally as a tablet.
• The typical dose is 600 mg (two 300 mg tablets) taken twice a day. However, the dosage may be adjusted based on the patient's individual response and side effects.
• Rubraca can be taken with or without food.
• Treatment with Rubraca is typically continued as long as the patient is responding well and experiencing manageable side effects.

Safety Concerns

• Rubraca may cause myelosuppression, leading to a reduction in the number of red blood cells, white blood cells, and platelets. Blood counts should be monitored regularly.
• Liver function should be monitored, as Rubraca can cause liver enzyme elevations in some patients.
• Common side effects include nausea, vomiting, and diarrhea. These are usually manageable but should be monitored.
• Many patients report experiencing fatigue or weakness while on Rubraca, which can affect quality of life.
• As with many cancer treatments, there is a potential risk of developing secondary cancers, such as leukemia or other blood-related disorders.

Avoid Rubraca (Rucaparib) If

• Do not use Rubraca if you have a known allergy to Rucaparib or any of its components.
• Rubraca should be avoided in patients with severe liver problems, as the medication may worsen liver function or cause further damage.
• If you have severe bone marrow suppression (e.g., low blood cell counts), Rubraca may not be suitable, as it could exacerbate the problem.
• Rubraca is contraindicated during pregnancy as it may harm the fetus. It should not be used by breastfeeding women, as the drug may pass into breast milk and affect the infant.
• Avoid using Rubraca with strong inhibitors or inducers of certain liver enzymes (e.g., CYP3A4), as these can alter the effectiveness of the drug or increase side effects.